Table 3.
Study / Date started | Status | Design | Condition | Intervention | Primary outcomes |
---|---|---|---|---|---|
NCT01654068 61 / Jul, 2012 | Recruiting | Phase II | Spinal metastasis | 1) 2-3 SM: 14 Gy SF2) 1 SM: 14 Gy SF | Any skeletal-related event |
NCT01223248 52 / Oct, 2012 | Recruiting | Phase III | Spinal metastasis | SR 24 Gy SF vs. SR, 27 Gy (HF) | Loco-regional control rates |
NCT01290562 62 / Jun 2011 | Recruiting | Phase II | Spinal metastasis | 20-24 Gy SF; or 20-24 Gy (HF)No prior RT or prior RT or Post-op | Local control: image / symptoms |
NCT00573872 63 / Dec 2007 | Not recruiting (active) | Phase I/II | Spinal metastasis | Phase 1: 20-25 Gy (HF) / Phase 2: 9-24 Gy (SF) | TT: Safety |
NCT01849510 64 / Apr 2013 | Recruiting | Phase II(2 arms) | Spinal metastasis | HF: 12×3 Gy+integrated boost 12×4 Gy / CRT 10×3 Gy | Local control |
NCT02167633 65 / Jul 2014 | Recruiting | Controlled (2 arms) | MSCC | Decompression surgery plus CRT / SR 16 Gy SF | Ambulatory status |
NCT00853528 66 / Feb 2009 | Not recruiting (active) | Phase I | Spinal metastasis | Maximum tolerated dose HF SR | Dose escalation |
NCT00631670 67 / Feb 2008 | Completed | Controlled | Spinal metastasis | 15 Gy SF / 25×2.8 Gy | Safety |
NCT01525745 68 / Jan 2012 | Completed | Phase II | Spinal metastasis | SR HF / CRT 10 fractions | Pain control: NPRS |
NCT01826058 69 / Apr 2013 | Recruiting | Phase II | MSCC | 16 -24 Gy SF / 21-36 HF | Neurologic response |
NCT01254903 70 / Dec 2012 | Recruiting | Phase I | MSCC | 18 Gy SF | Safety |
NCT00922974 9 / Nov 2009 | Recruiting | Phase II: completedPhase III | Spinal metastasis | SR 16 Gy SF / CRT 1×800 cGy | Pain control |
NCT01752036 71 / Mar 2013 | Recruiting | Phase II | Spinal metastasis | SR: 30 Gy (HF) | Safety |
NCT01347307 72 / Sep 2008 | Not recruiting(active) | Phase IV | Spinal metastasis | Benign: 12-16 Gy SF; 21-27 Gy HFMetastases: 14-25 Gy SF; 21-30 Gy HF | Tumor control |
NCT01231061 73 / Nov 2010 | Completed | Phase II | Spinal metastasis | Arm 1:SR 24 Gy HF / SR 16 Gy SF | Pain control |
NCT01950195 53 / Jun 2013 | Recruiting | Phase I | Spinal metastasis | SR+ipilimumab | Safety |
NCT01624220 74 / Jun 2012 | Recruiting | Assignment | Spinal metastasis | SR+4 gold seeds implanted | Safety |
SR: spine radiosurgery; NPRS: numeric pain rating scale; TT: tomotherapy; QA: quality assurance; SF: single fraction; HF: hypofractionated; CRT: conventional radiotherapy; Post Op.: post operative; MSCC: metastatic spinal cord compression.